Cell division cycle 25A (Cdc25A) was shown to colocalise both with nuclear and cytoplasmic proteins. Recently, we have demonstrated that overexpressed Cdc25A promoted the survival of rat 423 cells through indirect activation of PKBprotein kinase B. Using a Cdc25A:ER fusion protein, which can be shuttled from the cytoplasm into the nucleus, the present investigation evidences that the antiapoptotic effect of Cdc25A was restricted to its cytoplasmic localisation in rat 423 cells. In contrast, nuclear Cdc25A overexpression caused dephosphorylation and nuclear retention of the proapoptotic transcription factor Forkhead in rhabdomyosarcoma-like 1 (FKHRL1) in human N.1 ovarian carcinoma cells. This resulted in the increased constitutive expression of the FKHRL1 targets Fas ligand and Bim, and promoted apoptosis. Thus, the Cdc25A oncogene, which was found to be frequently overexpressed in certain human cancers, can increase or decrease the susceptibility to apoptosis depending on the cell-type-specific subcellular distribution.
Introduction
In a variety of malignant disorders, cell division cycle 25A (Cdc25A) is frequently overexpressed, [1] [2] [3] [4] and it has not been determined so far whether the pattern of overexpressed Cdc25A is confined to specific subcellular compartments in the distinct tumour entities. The family of Cdc25 dualspecificity phosphatases controls the cell cycle at different phases. [5] [6] [7] Cdc25A was shown to regulate G1-S transition by dephosphorylating threonine 14 and tyrosine 15 of cyclindependent kinase 2 (Cdk2), [8] [9] [10] [11] [12] [13] and by competition with p21 for cyclinA/Cdk2 and cylinE/Cdk2 binding sites. 14 Moreover, Cdc25A degradation is part of a DNA-damage checkpoint mechanism. 15 This implicates that Cdc25A activity is focused to the cell nucleus. However, Cdc25A also interacts with Raf1 by virtue of 14.3.3 proteins [16] [17] [18] and apoptosis signalregulating kinase (ASK) 1 . 19 This, in contrast, points to a cytoplasmic function of Cdc25A. It was demonstrated recently that in rat 423 cells the bulk of Cdc25A was actually localised in the cytoplasm and that apoptosis was inhibited by Cdc25A due to the PKB-protein kinase B (Akt) survival pathway activation. 18 In contrast, endogenous and ectopic Cdc25A is found in the nucleus in N.1 human ovarian carcinoma cells. The question arose as to how far the spatial distribution of Cdc25A is relevant for its antiapoptotic function.
Results

Distinct expression of Cdc25A in rat 423 cells and N.1 ovarian carcinoma cells
In earlier studies, it was shown that overexpressed Cdc25A promoted apoptosis in N.1 cells, 20 which in contrast was prevented in rat 423 cells. 18 Immunocytochemistry (Figure 1a ) and Western blot analysis of fractionated cell lysates ( Figure 1b) revealed that endogenous as well as ectopic Cdc25A was predominantly expressed in the cytoplasm in rat 423 cells, whereas it was restricted to the nuclei in N.1 cells. The analysis of two additional ovarian carcinoma cell lines (HTB-77, M-134) and two breast cancer cell lines (SKBr3 and T47D) revealed that these cell lines also expressed Cdc25A in the nucleus (Figure 1c) . Therefore, rat 423 cells were used for further studies regarding the cytoplasmic expression and function of Cdc25A.
Cdc25A causes dephosphorylation and activation of FKHRL1
analysed the expression and the phosphorylation status of the Forkhead transcription factor family members FKHR, Forkhead in rhabdomyosarcoma-like 1 (FKHRL1) and AFX (FOXO4) in Cdc25A-overexpressing N.1 cells, and in N.1-control cells. Tumour necrosis factor alpha (TNFa) induced the apoptosis of N.1 cells only under serum-deprived culture conditions. Therefore, all the analyses were performed with serum-starved cells. FKHR could not be detected in N.1 clones and AFX did not exhibit a distinct phosphorylation pattern in the cell clones analysed (data not shown). In N.1 cells, FKHRL1 accumulated in the nucleus under serumstarved conditions, which was also shown by others in different cell systems, 21, 22 and nuclear expression of FKHRL1 was further increased in Cdc25A-overexpressing cells (Figure 2a, Taken together, this implicated that Cdc25A mediated the dephosphorylation of FKHRL1 and caused its nuclear retention.
The slower migrating band of the pFKHRL1 double bands was not detected by the anti-pFKHRL1 antibody in Cdc25A-overexpressing N.1 cells after treatment with TNFa (indicated by an arrow, Figure 2a , second panel, compare lanes 3 and 7). This substantiated the former observation that nuclear overexpression of the phosphatase Cdc25A promoted the dephosphorylation of FKHRL1.
Only the nuclear localisation of the FKHRL1 transcription factor enables the transactivation of its target genes such as Bim and fasL 23, 25, 26 Western blot analyses of Bim, 26, 27 and FasL 23, 28 evidenced increased expression in N.1-Cdc25A cells compared to N.1 controls, whereas the expression of actin, which is not controlled by FKHRL1, remained unchanged (Figure 2b) .
It was shown that cytoplasmic Cdc25A indirectly activated Akt by inducing phosphorylation of Akt-threonine 473 presumably by involvement of Raf1. 18 Akt is a kinase regulating FKHRL1 phosphorylation, and Akt activity itself is regulated by phosphorylation. Therefore, the phosphorylation levels of Akt at serine 473 and at threonine 308 were investigated. Figure 2c demonstrates that neither of the two sites of Akt became differently phosphorylated in Cdc25A-overexpressing or N.1-control cells, which made an Akt-mediated alteration of FKHRL1 phosphorylation in Cdc25A-overexpressing cells unlikely.
Next, we investigated whether Cdc25A interacted directly with FKHRL1. A glutathione-S-transferase fusion construct (GST-FKHRL1), which was expressed in Escherichia coli, was bound to glutathione-sepharose and incubated with native N.1 cell lysate (containing a phosphatase inhibitor) and adenosine triphosphate (ATP) to phosphorylate GST-FKHRL1. However, the specific binding of Cdc25A (which was contained in native N.1 cell lysates as an endogenous protein) to FKHRL1 could not be detected. The faint Cdc25A bands showing up in the presence of GST-FKHRL1 and GST alone (control) were nonspecific contaminations, which remained trapped by sepharose (Figure 3) . Even the addition of 150-800 ng of recombinant active Cdc25A to phosphory- (Cdc25A) and N.1-control cells was isolated and separated on SDS-polyacrylamide gels, transferred onto PVDF membranes and immunoblotted with an antibody directed against phospho-serine 473 of Akt (p473Akt) and phospho-theronine 308 of Akt (p308Akt). For control reasons, the total Akt expression (Akt) was also investigated Figure 3 Interaction of Cdc25A with FKHRL1. GST-FKHRL1 and GST (for control reasons) was bound to glutathione-sepharose and incubated with native N.1 cell protein lysate and 1 mM ATP at room temperature for 20 min to phosphorylate GST-FKHRL1 (pGST-FKHRL1) and to promote the binding of Cdc25A to the potential substrate. Then, the incubation was terminated, GSTsepharose and GST-FKHRL1-sepharose were washed and centrifuged, resuspended in PAGE sample buffer, boiled and subjected to electrophoretic separation and Western blot analysis. The expression of GST and GST-FKHRL1 (Coomassie blue staining; left panel), the phosphorylation level of GST-FKHRL1 (middle panel) and the presence of Cdc25A (right panel) were analysed by Western blotting Cdc25A and apoptosis C Leisser et al lated GST-FKHRL1 did not show a specific interaction (data not shown). Furthermore, IP-Western assays, which were performed with native N.1 cell lysates, could not demonstrate a direct interaction of Cdc25A with FKHRL1 (data not shown). Therefore, the dephosphorylation of FKHRL1 in the presence of overexpressed Cdc25A was not mediated by a direct mechanism.
Cdc25A overexpression supports TNFa-induced apoptosis of N.1 cells
Increased FKHRL1 activity was expected to enforce an apoptotic response due to the transcription of FasL and Bim. 29 Therefore, apoptosis was measured in Cdc25A-overexpressing N.1 cells. To obtain comparable results, Cdc25A was introduced into N.1-pwzl cells by retroviral transduction (see 'Materials and Methods'). In N.1 cells, it was demonstrated that the induction of apoptosis by TNFa and benzamide riboside repressed endogenous Cdc25A. 30, 31 Hence, we analysed the expression of Cdc25A in the presence of TNFa by Western blotting to confirm that ectopic Cdc25A remained expressed ( Figure 4a ). This was essential for the performance of subsequent experiments. To determine cell death rates, N.1-Cdc25A and N.1-control cells, were exposed to TNFa for 96 h (Figure 4b ). On average, TNFa induced 23.8% cell death in control cells and 82.7% cell death in Cdc25A-overexpressing clone pools after 96 h (three independently pooled clones, triplicate experiments). Thus, in analogy to Myc-induced apoptosis, 32 there was also a Cdc25A-dependent increase in cell death rates. Also, in a particular subclone of Rat1 fibroblasts 33 and in vascular smooth muscle cells, 34 Cdc25A promoted apoptosis.
Cdc25A is known to activate Cdk2 and the improper activity of cell cycle protagonists (i.e. Cdk2) may be a potent apoptotic trigger. Therefore, the effect of Cdk2 overexpression on the induction of apoptosis was investigated. However, N.1 cells, in which cdk2 cDNA was stably introduced (Figure 5a ), did not show significant differences upon TNFa-induced apoptosis when compared to controls containing an empty vector (Figure 5b) . Also, rat 423 cells did not exhibit increased apoptosis rates when Cdk2 was overexpressed (data not shown).
Cytoplasmic expression of Cdc25A:ER promotes survival
To study the effect of cytoplasmic Cdc25A in a conditional model, the cDNA of Cdc25A was fused to a Tamoxifen (4-hydroxytamoxifen, 4-OHT)-responsive mutant of the oestrogen receptor (ER) resulting in a Cdc25A:ER construct. In the absence of 4-OHT, Cdc25A:ER localises in the cytoplasm. Therefore, a cell line was required, in which the nuclei were constitutively Cdc25A depleted (i.e. rat 423 cells), otherwise the nuclear expression of endogenous Cdc25A and cytoplasmic expression of ectopic Cdc25A:ER would have biased the readout of the survival assays. Since N.1 cells and the cell lines HTB-77, M-134, SKBr3 and T47D expressed endogenous Cdc25A in the nucleus, we had to use rat 423 cells, in which the nuclei were devoid of endogenous Cdc25A, and therefore the Cdc25A:ER fusion construct was stably transfected into this cell line. The ectopic expression of Cdc25A:ER was analysed by Western blotting with anti-ER and antiCdc25A antibodies (Figure 6a ). To confirm the conditional, 4-OHT-mediated translocation of Cdc25A:ER from the cytoplasm into the nuclei, cells were grown in 10% foetal calf serum (FCS), treated with 4-OHT for 2, 4 and 8 h, and then cytoplasmic and nuclear extracts were prepared and analysed by Western blotting. In response to 4-OHT, cytoplasmic Cdc25A:ER levels decreased time dependently and were redistributed into the nuclei, because the nuclear Cdc25A:ER level increased after 2 h of 4-OHT treatment. Unexpectedly, after 8 h of 4-OHT treatment, the nuclear expression levels of Cdc25A:ER decreased (Figure 6b ). After the induction of apoptosis by serum withdrawal, the survival rates of rat 423 control and Cdc25A:ER-expressing cells were determined. In previous investigations, it was shown that the ectopic overexpression of cytoplasmic Cdc25A prevented apoptosis of rat 423 cells, 18 and here we demonstrate that Cdc25A:ER also accumulated in the cytoplasm in the absence of 4-OHT and rendered rat 423 cells refractory to apoptosis (Figure 6c ). In the presence of 4-OHT (added 2 h after serum withdrawal), the antiapoptotic effect of Cdc25A:ER was reverted. Hence, Cdc25A prevented apoptosis only when it was localised in the cytoplasm. The proapoptotic effect of nuclear Cdc25A:ER (upon 4-OHTmediated relocation) was weak, because Cdc25A:ER became rapidly degraded in the nuclei of 423 cells, but it was significant (see Figure 6c ).
Discussion
Former work regarding the function of Cdc25A raised indirect evidence for its ubiquitous distribution within cells. On the one hand, Cdc25A was described as a key regulator of G1-S transition by dephosphorylating Cdk2 8 
In rat 423 cells, the bulk of anti-Cdc25A immunostaining was in fact localised in the cytoplasm. 18 This was confirmed by immunoblotting rat 423 nuclear and cytoplasmic protein extracts (Figures 1a and b) . In rat 423 cells, cytoplasmic Cdc25A was shown to activate the Akt-survival pathway indirectly, thereby preventing apoptosis. 18 Another report demonstrated that Cdc25A inhibited cytoplasmic ASK1 independent of its phosphatase activity, thereby blocking cell death triggered by oxidative stress. 19 Hence, we fused the cDNA of Cdc25A to that of ER, which allows for Tamoxifen (4-OHT)-mediated shuttle of the Cdc25A:ER protein from the cytoplasm into the nucleus. The results from this investigation suggested that Cdc25A protected from apoptosis only when it was localised in the cytoplasm, because upon 4-OHT treatment, the cytoplasmic Cdc25A:ER level diminished and increased in the nuclei of rat 423 cells within 2 h, followed by degradation within 8 h. Hence, the loss of antiapoptotic function of Cdc25A:ER correlated with the decreased cytoplasmic expression upon exposure to 4-OHT. The rapid nuclear degradation of imported Cdc25A:ER (mediated by 4-OHT) may explain why the proapoptotic effect of (short-lived) nuclear Cdc25A:ER was weak (but significant).
Upon treatment with 4-OHT, the decay of nuclear Cdc25A:ER might have been triggered by the ER portion and ubiquitination of ER might have also tagged Cdc25A to proteasomal degradation. The stability of ER was shown to depend on the type of ligand bound to ER and on the cellular context. 35 Alternatively, Cdc25A itself might have been the prime target for proteolytic degradation as soon as it was relocalised to the nucleus of rat 423 cells. Since the bulk of endogenous Cdc25A was found in the cytoplasm, but not in the nuclei of rat 423 cells, this favours the possibility of nucleus-specific proteolysis of Cdc25A in this cell line and makes rat 423 cells a valuable tool to study spatial functions of Cdc25A. Furthermore, Cdc25A contains both a nuclear localisation signal and a nuclear export signal, and it is possible that either of the two mechanisms might be dysregulated, thereby causing a decrease in nuclear Cdc25A levels. Future work in our lab will focus on the subcellular expression of Cdc25A in distinct cell types and on physiological relocation mechanisms.
As pointed out in this investigation, Cdc25A accumulated a priori in the nuclei of N.1 human ovarian carcinoma After withdrawal of serum for 24 h, the independent clones were exposed to 40 ng/ml TNFa for 96 h. Then, adherent cells were trypsinised and counted. The marginal differences in the survival rates of control and Cdk2-overexpressing N.1-pwzl clones were not significant (t-test). Error bars indicate S.E.M.
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C Leisser et al 18 we did not observe that ectopic Cdc25A was expressed beyond two-to three-fold over endogenous expression. We assume that excessive (nuclear) expression has adverse effects for these cells, and therefore such clones, which vastly overexpress Cdc25A, will vanish by negative selection. Surprisingly, even in rat 423 cells, in which Cdc25A was shown to predominate in the cytoplasm and protects from apoptosis, only a two-to three-fold overexpression was observed in a panel of 12 independent Cdc25A overexpressing clones. This suggests that in various cell types, only a limited level of Cdc25A expression is tolerated and further implicates that Cdc25A seems to be a fine-tuned key regulator (perhaps even rate limiting) for different cellular processes. This assumption is supported by the fact that even moderate overexpression of Cdc25A caused dramatic effects that are beyond a direct correlation with respect to the expression level. Interestingly, the constitutive Cdc25A-expression levels of HTB-77 versus M-134 ovarian carcinoma cells differed by a factor of B10. It can be speculated that HTB-77 possess an appropriate (distorted) genetic background, which allows for this high Cdc25A expression without adverse effects.
This investigation furthermore demonstrates that at least phospho-threonine 32 of FKHRL1, which targets FKHRL1 for 14.3.3-mediated cytoplasmic export, became dephosphorylated upon nuclear Cdc25A overexpression in N.1 cells. FKHRL1 is a transcription factor 23, 28, 36, 37 and to be active its nuclear abundance is mandatory. Also phosphorylation at serine 253 defines cytoplasmic localisation by disrupting a nuclear localisation signal (NLS) on FKHRL1. 36 Both phosphorylation sites may cooperate in determining the subcellular distribution of FKHRL1. The regulatory functions of phosphorylated serine 315 and of other phosphosites are currently unknown. Dephosphorylation of FKHRL1 is necessary for its nuclear retention and in fact the level of nuclear FKHRL1 was elevated in Cdc25A-overexpressing N.1 cells. This may have caused the activation of FasL 28, 23 and Bim transcription, 27, 26 and the enhanced apoptotic response in Cdc25A-overexpressing N.1 cells. The dephosphorylation of FKHRL1 requires a direct interaction with phosphatase(s). However, neither in vitro binding studies with a GST-FKHRL1 fusion protein nor pulldown assays from native cell extracts (data not shown) confirmed direct binding of Cdc25A to FKHRL1. Hence, Cdc25A seems unlikely to dephosphorylate FKHRL1 itself, but to either induce another phosphatase or to inactivate a kinase that regulates FKHRL1 phosphorylation. It was reported that FKHRL1 becomes directly phosphorylated by kinases such as Akt, 23, 28, 38, 39 whereas PTEN mediates indirect dephosphorylation of FKHRL1. 40 In conclusion, this study demonstrates that the nuclear overexpression of Cdc25A indirectly mediated the dephosphorylation of threonine 32 of FKHRL1 and promoted apoptosis, whereas the cytoplasmic overexpression of Cdc25A was apoptosis protective.
Since numerous human cancers overexpress Cdc25A, [1] [2] [3] [4] the determination of the spatial expression may be relevant to evaluate its impact on prognosis and therapy.
Materials and Methods
Materials
Human cdc25A cDNA was a kind gift from Dr. David Beach (Cold Spring Harbour Laboratories, NY, USA), cdk2 cDNA was a gift from Dr. Hannes Hofmann (IMP, Vienna), the pBabe-puro (pBpuro) vector was a gift from Dr. Trevor Littlewood (ICRF, London, UK), the GST-FKHRL1 fusion construct was a gift from Dr. Anne Brunet (Harvard, Boston, USA) and the pwzl plasmid was a gift from Dr. 
Cell culture
Ovarian carcinoma cell lines HTB-77 and M-134 were grown in alpha-MEM, the breast cancer cell line SKBr3 was grown in McCoys medium and the breast cancer cell line T47D and rat 423 cells were grown in DMEM, all containing 10% FCS and 1% penicillin-streptomycin. Rat 423-Cdc25A:ER cells were grown in DMEM containing 10% FCS, 1% penicillin-streptomycin and 2 mg/ml puromycin.
The monoclonal human ovarian adenocarcinoma N.1 cell line is a derivative of the heterogeneous HOC-7 cell line that was cultured in MEM supplemented with 10% FCS (GIBCO, Paisley, UK), penicillin-streptomycin (100 U/ml-100 mg/ml, Gibco-BRL) (medium A), at 371C in a humidified atmosphere containing 5% CO 2 .
N.1-pwzl cells were grown in MEM containing 200 mg/ml G-418 sulphate.
N.1-pwzl-Cdc25A and N.1-pwzl-Cdk2 cells (both in pBpuro), and N.1-pwzl-pBpuro cells (control) were grown in a-MEM with the addition of 0.4 mg/ml puromycin and 200 mg/ml G-418 sulphate.
Subcloning procedures
The cdc25a or egfp (for control reasons) cDNA was subcloned into the XhoI and NotI site of the pCI neo mammalian expression vector, which contains a CMV promotor (Promega, Mannheim, Germany) or blunt end ligated into the SnaBI site of pBpuro.
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Cdc25A:ER construction: The cdc25a cDNA was released from the pBluescript vector with BssHII and BsrGI. In all, 5 0 overhangs were filled with Klenow and ligated into the Klenow-filled BamHI site of Myc:ER that is inserted in the pBpuro vector (BamHI releases myc from this construct, which was a kind gift of Trevor Littlewood 41 ). The correct reading frame was checked by DNA sequencing. C-terminal loss of six amino acids does not infringe the active centre of the Cdc25A phosphatase domain.
Transfection of cells
Rat 423 cells were plated into 60 mm dishes and grown for 2 days to 40-50% confluence. Lipofection of cells with Cdc25A:ER cDNA (in pBpuro) was performed utilising the Transfectam reagent (Promega). The cells were washed once with prewarmed DMEM without FCS. A total of 5 mg DNA (1 mg/ml) and 10 ml Transfectam were separately pipetted into 0.75 ml DMEM each and then both mixtures were combined. Transfectam-DNA complexes were allowed to form for 10 min and were then applied onto rat 423 cells for 3 h in a humidified incubator. The transfection was stopped by adding 4 ml DMEM containing 10% FCS. The next day, the cells were split into new dishes with a fresh medium and 48 h after transfection, selection drug 2 mg/ml was added and single clones were isolated with cloning cylinders and were propagated separately. Where indicated, pooled clones were propagated.
Generation of ecotropic mouse retrovirus transducible N.1 human ovarian carcinoma cells N.1 cells were stably pretransfected with mouse retrovirus receptor (pwzl, G-418 selection) and then various single clones were infected with EGFP. Those clones, which expressed functional pwzl (identified by green fluorescence when inspected under UV light in conjunction with a fluorescein isothiocyanate (FITC) filter), were pooled and used for control reasons. The parental clones, which were identified by this assay (N.1-pwzl) to express the functional retrovirus receptor, were also pooled and this pooled clone was subsequently infected with ectopic mouse retrovirus containing Cdc25A. This procedure generated five independent Cdc25A pools from two independently packaged retrovirus stocks. Cdc25A overexpression was tested by Northern and Western blot analyses.
Production of retrovirus titre
Phoenix cells were grown in 100 mm dishes in DMEM, supplemented with 10% FCS and 50 mg/ml hygromycin B. The transfection procedure (Transfectam) was upscaled for 100 mm dishes and performed, as described in the Promega protocol. The cells were transfected at 80% confluence with 12.5 mg plasmid DNA (concentration 1 mg/ml) in 37.5 ml Transfectam (1 : 3 ratio w/vol). After 1 h of incubation, the medium was replaced by 10 ml fresh medium with 10% FCS. After 24 h, the medium was replaced with 4 ml of complete medium (10% FCS). At 48 h after transfection, the retrovirus containing cell culture supernatant was filtered (0.22 mm filter), aliquoted, shock-frozen in liquid nitrogen and stored at À801C.
Infection of cells
N.1-pwzl cells were grown in six-well plates to 50% confluence. A measure of 500 ml virus suspension was mixed with 500 ml MEM, containing 10% FCS. Then Polybrene (Sigma) was added to a final concentration of 4 mg/ml. After an infection period of 3 h in the cell culture incubator, 2 ml of MEM with 10% FCS was added. After 24 h, cells were transferred into larger dishes to allow cell growth. At 48 h after infection, a selective medium (1 mg/ml puromycin, Sigma) was added to kill noninfected cells. After 10-12 days of selection, the puromycin concentration was reduced to 0.4 mg/ml.
Several independent Cdc25A and control pools of infected N.1-pwzl cells were used for further experiments.
Immunocytochemistry
Cell clones were grown on siliconised glass slides. Then, cells were washed twice with phosphate-buffered saline (PBS) (pH 7.2), air-dried, fixed with ice-cold acetic acid : ethanol (1 : 3) for 10 min and permeabilised with Triton X-100 (0.5% in PBS) for 3 min at room temperature. Then slides were washed three times with washing buffer (0.5 M Tris-HCl, pH 7.5) to remove Triton X-100. Anti-Cdc25A rabbit polyclonal antibody was diluted in 0.5 M Tris buffer, 1% BSA pH 7.5 (anti-Cdc25A antibody dilution was 1 : 50 of a 100 mg/ml stock) and incubated in a humid chamber for 1 h at room temperature. After washing, the slides were incubated with FITCconjugated second antibody (goat anti-rabbit IgG, dilution 1 : 30; Dako) for 30 min. Finally, slides were covered with a mounting medium (Geltol mounting medium for fluorescence, Lipshaw) and a coverslip. For control, slides were exposed to the second antibody only.
Nucleus-cytoplasm fractionation
Cells were washed in PBS and lysed in buffer A (10 mM, (HEPES), 10 mM KCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mM EGTA, 1 mM DL-dithiothreitol (DTT), 1.5% NP-40, PIM, phenylmethylsulphonyl fluoride (PMSF)), on ice for 10 min and centrifuged at 12 000 rpm. Supernatants were collected as cytoplasmic extracts.
The pellets were washed, resuspended in buffer B (20 mM HEPES, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.05% NP-40, PIM, PMSF) and agitated at 41C for 20 min. After centrifugation at 12 000 rpm, the supernatants were collected as nuclear extracts. The extracts were analysed by Western blotting.
Western blotting
Experiments were terminated by washing attached cells twice with ice-cold PBS (pH 7.2) and harvesting the monolayer with 200 ml sodium dodecyl sulphate (SDS) sample buffer, or with the buffers indicated. The viscous samples were sonicated and equal amounts of total protein were separated by polyacrylamide gel electrophoresis (PAGE). Subsequent to the electrophoretic separation, the proteins were electroblotted onto PVDF-membranes (Hybond, Amersham) overnight at 41C. To confirm equal sample loading, membranes were stained with Poinceau S. After washing with PBS or TBS, membranes were blocked for 1 h (blocking solution: 5% nonfat dry milk in PBS containing 0.5% Tween-20 or in TBS containing 0.1% Tween-20) and washed 3 Â with PBS/Tween-20 (PBST) or TBS/Tween-20 (TBST). Then, membranes were incubated with the first antibody (in blocking solution) by gently rocking at 41C, overnight. Thereafter, the membranes were washed in blocking solution (1 Â ) and in PBS/TBST (2 Â ) and further incubated with the second antibody (peroxidase-conjugated goat anti-rabbit IgG or anti-mouse IgG, dilution 1 : 2000-1 : 5000 in PBST or TBST; Calbiochem) for 1-2 h. Chemoluminescence was developed by the ECL detection kit (Amersham, UK) and then membranes were exposed to Kodak X-OMAT UV films.
